Old Web
English
Sign In
Acemap
>
authorDetail
>
Marcia Kayath
Marcia Kayath
Novartis
Nilotinib
Immunology
Internal medicine
Imatinib
Adverse effect
3
Papers
43
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Comment on: "Is this a 737 Max Moment for Brolucizumab".
2020
American Journal of Ophthalmology
Marcia Kayath
Dirk Sauer
Show All
Source
Cite
Save
Citations (2)
Efficacy and Safety of Nilotinib In Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (Pts) with Type 2 Diabetes In the ENESTnd Trial.
2010
Blood
Giuseppe Saglio
Richard A. Larson
Timothy P. Hughes
Surapol Issaragrisil
Turkina Ag
David Marin
Maria Aparecida Zanichelli
Hirohiko Shibayama
Matt Kalaycio
F. Rigal-Huguet
Neil Gallagher
Marcia Kayath
Ming Zheng
Hagop M. Kantarjian
Andreas Hochhaus
Show All
Source
Cite
Save
Citations (32)
Analysis of Glucose Profiles in Imatinib-Resistant or Intolerant Chronic Myelogenous Leukemia (CML) Patients (pts) Treated with Nilotinib: Lack of Correlation between Glucose Levels and Nilotinib Efficacy.
2007
Blood
Philipp le Coutre
Francis J. Giles
Andreas Hochhaus
Giovanni Martinelli
Jim Wang
Vanessa Q. Passos
Marcia Kayath
Michele Baccarani
Hagop M. Kantarjian
Show All
Source
Cite
Save
Citations (9)
1